Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis.
Biliary pseudolithiasis has been reported in patients who received ceftriaxone therapy. In addition to biliary sludge formation occasional reports of ceftriaxone-induced nephrolithiasis have been published. In general, these adverse effects will develop after seven to ten days of treatment. We report on a seven-year-old boy with ceftriaxone-associated biliary pseudolithiasis and nephrolithiasis four days after initiation of treatment. Patients receiving a high dose of ceftriaxone and developing colicky abdominal pain should be considered for ultrasound and a change in antibiotic therapy if appropriate.
de Moor
R A
RA
Department of Pediatrics, Tweesteden Hospital, PO Box 90107, 5000 LA Tilburg, The Netherlands.
Egberts
A C
AC
Schröder
C H
CH
D001649:Bile Duct Diseases / Q000139:chemically induced*; D002443:Ceftriaxone / Q000009:adverse effects* / Q000627:therapeutic use; D002511:Cephalosporins / Q000009:adverse effects* / Q000627:therapeutic use; D002648:Child; D003937:Diagnosis, Differential; D006801:Humans; D007669:Kidney Calculi / Q000139:chemically induced*; D020347:Lithiasis / Q000139:chemically induced*; D008297:Male; D016920:Meningitis, Bacterial / Q000188:drug therapy / Q000382:microbiology; D009345:Neisseria meningitidis / Q000302:isolation & purification
D002511:Cephalosporins; D002443:Ceftriaxone